1	Multilevel determinants of Covid-19 vaccine hesitancy and undervaccination among
2	marginalized populations in the United States: A scoping review
3	
4	Peter A. Newman <sup>1*</sup> , Thabani Nyoni <sup>1</sup> , Kate Allan <sup>1</sup> , Sophia Fantus <sup>2</sup> , Duy Dinh <sup>3</sup> , Suchon Tepjan <sup>4</sup> ,
5	Luke Reid <sup>1</sup> , Adrian Guta <sup>5</sup>
6	
7	<sup>1</sup> Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada
8	<sup>2</sup> School of Social Work, University of Texas at Arlington, Texas, USA
9	<sup>1,3</sup> Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada
10	<sup>1,4</sup> VOICES-Thailand Foundation, Chiang Mai, Thailand
11	<sup>5</sup> School of Social Work, University of Windsor, Windsor, Ontario, Canada
12	
13	*Corresponding author

14 E-mail: <u>p.newman@utoronto.ca</u>

# 15 Abstract

16 Background: Amid persistent disparities in Covid-19 vaccination, we conducted a scoping 17 review to identify multilevel determinants of Covid-19 vaccine hesitancy (VH) and 18 undervaccination among marginalized populations in the U.S. 19 Methods: We utilized the scoping review methodology developed by the Joanna Briggs Institute 20 and report all findings according to PRISMA-ScR guidelines. We developed a search string and 21 explored 7 databases to identify peer-reviewed articles published from January 1, 2020–October 22 31, 2021, the initial period of U.S. Covid-19 vaccine availability. We combine frequency 23 analysis and narrative synthesis to describe factors influencing Covid-19 vaccination among 24 marginalized populations. 25 **Results:** The search captured 2,496 non-duplicated records, which were scoped to 50 peer-26 reviewed articles: 11 (22%) focused on African American/Black people, 9 (18%) people with 27 disabilities, 4 (8%) justice-involved people, and 2 (4%) each on Latinx, people living with 28 HIV/AIDS, people who use drugs, and LGBTO+ people. Forty-four articles identified structural 29 factors, 36 social/community, 27 individual, and 40 vaccine-specific factors. Structural factors 30 comprised medical mistrust (of healthcare systems, government public health) and access 31 barriers due to unemployment, unstable housing, lack of transportation, no/low paid sick days, 32 low internet/digital technology access, and lack of culturally and linguistically appropriate 33 information. Social/community factors including trust in a personal healthcare provider (HCP), 34 altruism, family influence, and social proofing mitigated VH. At the individual level, low 35 perceived Covid-19 threat and negative vaccine attitudes were associated with VH. 36 **Discussion:** This review indicates the importance of identifying and disaggregating structural 37 factors underlying Covid-19 undervaccination among marginalized populations, both cross-

- 38 cutting and population-specific—including multiple logistical and economic barriers in access,
- 39 and systemic mistrust of healthcare systems and government public health-from individual and
- 40 social/community factors, including trust in personal HCPs/clinics as reliable sources of vaccine
- 41 information, altruistic motivations, and family influence, to effectively address individual
- 42 decisional conflict underlying VH as well as broader determinants of undervaccination.
- 43

### 44 Keywords

- 45 Vaccination hesitancy, Covid-19 vaccines, medical mistrust, social determinants of health,
- 46 access to care, ethnic and racial minorities

# 47 Introduction

48	Vaccination remains an essential component of public health strategies to control the
49	Covid-19 pandemic. Vaccination has reduced Covid-19-related morbidity and mortality in the
50	United States (U.S.) [1], and globally-with an estimated 63% (14.4-19.8 million) reduction in
51	deaths in the first year of Covid-19 vaccination alone [2]. Vaccine booster doses [3], and bivalent
52	vaccine boosters compared with past monovalent vaccination [4], have further reduced Covid-
53	19-associated hospitalization and death. Yet, despite the tremendous successes of Covid-19
54	vaccination, pervasive challenges ascribed to vaccine hesitancy (VH), and broader Covid-19
55	undervaccination, threaten the effectiveness of vaccines in controlling Covid-19 and other
56	vaccine-preventable diseases.
57	The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on
58	Immunization defines vaccine hesitancy (VH) as "delay in acceptance or refusal of vaccination
59	despite availability of vaccination services" [5,p.4161]. In addition to individual-level correlates
60	of VH, SAGE [6] along with other research initiatives [7,8] have drawn attention to the critical
61	importance of vaccine availability and access-amid systematic variations in vaccine coverage
62	across countries and subpopulations-and issues that may pertain to specific vaccines.
63	Collectively, these challenges support the need to identify and examine multilevel factors that
64	contribute to Covid-19 VH and broader Covid-19 undervaccination (e.g., due to inaccessibility,
65	unavailability) [9].
66	Disparities in Covid-19 morbidity and mortality, as well as lower rates of Covid-19
67	vaccination, are well documented among marginalized populations in the U.S. [10-13].
68	Marginalization is defined by systemic processes driven by ideologies such as racism, sexism,
69	heterosexism, cissexism, ableism, and xenophobia, that exclude certain populations or relegate

70	them to the periphery of political and socioeconomic resources [14,15]. The structural and social
71	inequities produced by marginalization create adverse social determinants of health (SDOH)-
72	such as residential segregation and housing insecurity, employment precarity, income insecurity,
73	lack of access to affordable healthcare, barriers to physical mobility, and stigmatization-all of
74	which increase vulnerability to poor health outcomes [14]. Adverse SDOH exacerbate
75	vulnerability to Covid-19 through the disproportionate prevalence of underlying conditions
76	associated with worse Covid-19 outcomes, lower levels of health insurance and healthcare
77	access, and by impeding the ability to practice public health measures to reduce viral
78	transmission [16-19]. Although heightened vulnerability indicates an increased need for
79	vaccination, these same SDOH may contribute to <i>lower</i> levels of Covid-19 vaccination [20,21].
80	In fact, across 45 U.S. states, 0.1%–24.9% lower vaccination was documented among Blacks vs.
81	Whites, 0.0%–37.6% lower among Hispanics vs. Whites, as of May 2021—with state-level rate
82	differences significantly associated with a metric of structural racism [21]. In a national study,
83	eligible healthcare facilities and community pharmacies in counties with higher Black
84	composition were significantly less likely to provide Covid-19 vaccination [20].
85	Although some of the racial/ethnic disparities in Covid-19 vaccination documented
86	earlier in the pandemic have reportedly narrowed over time, attributed in part to the success of
87	targeted interventions [11], disparities persist in lower administration of booster doses among
88	Black, Hispanic/Latinx, and American Indian populations versus Whites [22]. Consistent with
89	the "inverse equity hypothesis," with each innovation in Covid-19 vaccines, uptake is predicted
90	to be greater among wealthier and more socially connected segments of the population, thereby
91	increasing rather than reducing inequity [23,24]. Nevertheless, population-level disparities in
92	Covid-19 vaccination are often conceptualized as contingent on individual-level factors (e.g.,

93	low perceived threat, vaccine attitudes) to the relative underemphasis of structural and systemic
94	factors [20,21,25,26]. Moreover, trust/mistrust in a personal HCP as a source of reliable
95	information [27] is often conflated with systemic medical mistrust: distrust of healthcare
96	systems, government public health, medical treatments, and/or the pharmaceutical industry
97	arising from present-day experiences of discrimination and/or historical experiences of
98	discrimination and injustice in the healthcare system [28-30].
99	Building on the SAGE "Vaccine Hesitancy Determinants Matrix" and recommendations
99 100	Building on the SAGE "Vaccine Hesitancy Determinants Matrix" and recommendations to approach VH as a population- and context-specific phenomenon [6,31], along with critiques of
100	to approach VH as a population- and context-specific phenomenon [6,31], along with critiques of
100 101	to approach VH as a population- and context-specific phenomenon [6,31], along with critiques of the lack of clarity in the definition and application of VH [32-34], we conducted a scoping

# 105 Methods

A scoping review was conducted given our aim of mapping the evidence landscape [35] on factors associated with Covid-19 VH and undervaccination among marginalized populations. A scoping review protocol, including our search strategy and review process, has been previously published [36]. We utilized the scoping review methodology described by Arksey and O'Malley [37], further developed by the Joanna Briggs Institute [38], with all results reported in accordance with PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines [39].

112

## 113 **Research question**

114 This scoping review was guided by the question, "What are the determinants of Covid-19 115 'vaccine hesitancy' reported among marginalized populations in the U.S. and Canada?", with

sub-questions, "what are the focal populations in studies of Covid-19 VH and undervaccination
among marginalized populations?" and "what are the contexts and determinants of Covid-19 VH
and undervaccination by structural, social and community, individual, and vaccine-specific
factors?" [36].

120

## 121 Information sources and search strategy

122 We identified the following list of databases to search in consultation with a specialist 123 research librarian: Medline, Embase, Cochrane CENTRAL, Cochrane Covid-19 Study Register, 124 PsychINFO, Sociological Abstracts, and the International Bibliography of the Social Sciences 125 (IBSS). We then developed a search string with keywords and synonyms related to vaccine hesitancy (i.e., "vaccine hesitancy", "vaccine refusal", "vaccine confidence", "vaccine distrust", 126 127 "vaccine mistrust", "vaccine barriers") and Covid-19 (i.e., "corona virus" or "coronavirus" or "COVID" or "nCoV" along with adjacent terms "19" or "2019, or "SARS-CoV-2" or "SARS 128 129 Coronavirus 2", etc.). S1 Table shows an example search string for Medline and Embase. We 130 adapted the search string to accommodate differences in syntax and parameters among the 131 selected databases.

132

# 133 Study selection criteria

We developed inclusion and exclusion criteria prior to conducting the search for peerreviewed articles published between January 1, 2020 and October 31, 2021: 1) populations in the
U.S. or Canada; 2) adults ≥18 years; 3) focused on (>50%) marginalized populations, 4) focused
on Covid-19 vaccine hesitancy, refusal, confidence, mistrust, or barriers. Articles were excluded
if they were 1) published prior to 2020; 2) not written in English; 3) focused on healthcare

139	workers, staff, or students/interns; or 4) focused on children (<18 years) or parents' vaccination
140	of children. We selected search dates corresponding to the declaration of Covid-19 as a public
141	health emergency through the initial authorization of Covid-19 vaccines for the adult population
142	in the U.S. and Canada in December 2020, until U.S. FDA and Health Canada recommendations
143	for the first booster vaccines, beginning in late September 2021 to early November 2021 [40,41].
144	We identified marginalized populations informed by a review of populations particularly
145	vulnerable to discrimination and exclusion in healthcare [42] or due to broader adverse SDOH
146	[14]. The populations include those marginalized in relation to their race or ethnicity, sexual
147	orientation or gender identity, physical or mental disability, persons living with HIV,
148	immigrants/refugees, persons who experience homelessness, justice-involved people, and people
149	who use drugs, along with their intersections (e.g., Latinx immigrants).
150	

150

#### **Study selection process** 151

152 Search results of peer-reviewed articles were uploaded into Covidence software. Multiple 153 research team discussions ensured consistent application of inclusion/exclusion criteria. Initially 154 groups of two reviewers (among LR, TN, DD, KA, SF or ST) independently screened abstracts 155 and titles until we attained inter-rater reliability of 90% [43]; this was achieved after two rounds 156 of abstract review and team discussions to achieve consensus. Subsequently, in accordance with 157 rapid review methods, one reviewer screened each abstract/title to determine inclusion or 158 exclusion [44]. One reviewer (TN, DD, KA, SF or ST) then screened each full-text for inclusion. 159 Full-text articles designated for exclusion were then reviewed by a single arbitrator (PN), with 160 discrepancies resolved by consensus among the research team [44,45].

## 162 Data extraction and synthesis

163 We abstracted data on publication characteristics (i.e., author(s), study sites, sample size, 164 populations, methods, and domains of VH factors identified (see Table 1). We then reviewed the 165 abstracted data using quantitative (i.e., frequency) analysis to describe study locales, sample 166 sizes, focal populations, methods, and VH factor domains, and qualitative (i.e., narrative) 167 analysis to synthesize the evidence on VH and undervaccination among each subpopulation. 168 All authors categorized publications by domains of factors identified, using a four-169 component framework informed by the "Vaccine Hesitancy Determinants Matrix" [6.31] and 170 recommendations to disaggregate multilevel phenomena [8,33,34]. Domains comprised 171 structural (e.g., access to vaccination site, medical mistrust); social/community (e.g., family 172 support, trust in personal HCP or clinic, social proofing [i.e., based on actions of others in one's 173 community], community benefits); individual (e.g., perceived Covid-19 threat, perceived 174 transmission risk, general vaccine beliefs); and Covid-19 vaccine-specific factors (e.g., vaccine 175 safety, side effects, efficacy). One change to data extraction (but not inclusion) was made from 176 the initial protocol in that we differentiated between medical mistrust at the "system-level" and 177 trust in a personal HCP/clinic.

178

# 179 **Results**

The search captured 4,399 peer-reviewed articles in total, with 2,496 abstracts screened after removal of duplicates. We identified 363 full-text articles to be screened for eligibility, with a total of 50 peer-reviewed articles included [12,26,46-93]. The PRISMA flow diagram shows the process of identifying relevant peer-reviewed journal articles (see Fig 1).

#### 185 Figure 1. PRISMA flow diagram for scoping review of COVID-19 vaccine hesitancy and

#### 186 undervaccination among marginalized populations

187

# 188 **Description of studies**

- Among the 50 articles included, 86% were quantitative studies, 10% qualitative, and 4% mixed
- 190 methods (see Table 1). Sample sizes ranged from n=24 to n=164,283 (N=499,237; median=437).
- 191 All studies were conducted in the U.S., including 24 (48%) national studies, 8 (16%) in the West,
- 192 7 (14%) Northeast, 5 (10%) Midwest, 5 (10%) Southeast, and 1 (2%) in the Southwest region.
- 193 No studies were identified from Canada that met inclusion criteria within the timeframe of the
- 194 review.

# 195 Table 1. Study characteristics, focal populations, and domains of Covid-19 vaccine hesitancy and undervaccination among

196 marginalized populations in the U.S., January 1, 2020 to October 31, 2021 (n = 50 articles)

Author(s)	Sample Size	Region	Study Setting	Focal Population(s)		Methods	6		Domains	of VH	
					Quant	Qual	Mixed	Structural	Social/ Community	Individual	Vaccine- specific
Allen	396	National	Online	Racial/ethnic min.	X				(+)		(-)
Arvanitis	601	MW	Telephone: Chicago, IL	Racial/ethnic min.	x			(-)		(+)	
Balasuriya	72	NE	Online: New Haven, CT	AA/Black & Latinx		x		(-)	(+)		
Battarbee	915	National	Online	Racial/ethnic min.	x			(-)	(+)		(-)
Bauer	3743	SW	Data obtained from the City of Brownsville Public Health Department	Latinx	x						
Bogart	101	W	Telephone: Los Angeles, CA	AA/Black and PLHA	X			(-)	(+)		(-)
Bogart	207	National	Online	AA/Black	x			(-)	(+)		(-)
Carson	70	W	Online: Los Angeles, CA	Racial/ethnic min.		X		(-)	(+/-)		(-)
Chin	97779	W	Data obtained from the CDCR vaccination program in California State Prisons	Л	X			(-)		(-)	(-)
Clark	224	MW	Clinic: Kansas City, MO	Racial/ethnic min.	x			(-)		(+)	(-)
Crozier	3721	SE	Telephone/Online: Alabama	AA/Black	x			(-)			
Ehde	486	National	Online	PWD	x			(+)	(+)	(+)	
Ehde	359	National	Online	PWD	x			(+)		(+)	(-)
Fernandez-Penny	1068	NE	Hospitals: Philadelphia, PA	AA/Black	X			(-)	(+)		(-)

Fisher	1668	National	Online	Racial/ethnic min.	Х				(+)		
Garcia	1515	National	Online: US Hemodialysis Facilities	Racial/ethnic min.	Х				(+/-)	(-)	(-)
Garcia	46	W	Telephone: OR	Latinx		x		(-)	(+)		(-)
Geana	25	MW	Telephone: Midwest USA	Л		X		(-)	(-)	(-)	(-)
Ghaffari-Rafi	359	W	Telephone: HI	PWD	X			(-)	(-)	(+)	(-)
Guidry	788	National	Online	Racial/ethnic min.	х			(-)			(-)
Hagan	164,283	National	Data obtained from Electronic Medical Records in Federal Bureau of Prisons	JI	X			(+/-)	(+)	(-)	(+)
Iadarola	825	NE	Online: NY	PWD	х			(-)	(-)	(-)	(-)
Jimenez	111	NE	Online: NJ	AA/Black & Latinx	х			(-)	(-)		(-)
Johnson	248	SE	Clinic: Baton Rouge, LA	AA/Black	Х			(-)	(-)		(-)
Jones	94	SE	Telephone/Online: Miami, FL	PLHA	Х			(-)	(+)	(+/-)	(-)
Kricorian	1950	National	Online	AA/Black & Latinx	x			(-)	(+)		(-)
Kuhn	90	W	Telephone: Los Angeles, CA	РЕН	Х			(-)	(-)	(-)	(-)
Luo	6715	National	Data obtained from the Medicare Current Beneficiary Survey	PWD	Х			(-)		(+)	(-)
Masson	258	W	California residential substance use treatment programs	PWUD	Х			(-)		(+)	(-)
Momplaisir	24	NE	Online: Philadelphia, PA	AA/Black		x		(-)	(+/-)	(-)	(-)
Moore	257	SE	Community Events: The Central Savannah River Area	AA/Black	х			(-)		(-)	
Myers	439	National	Online	PWD	x			(-)	(+)	(+)	(-)
Okoro	183	MW	Online: MN and WI	AA/Black			X	(-)	(+/-)	(-)	(-)
Razzaghi	135,968	National	Data obtained from the Vaccine Safety Datalink (VSD)	Racial/ethnic min.	X			(-)			(-)

Rodriguez	2301	National	Emergency Departments in Hospitals	Racial/ethnic min.	X		(-)	(-)		(-)
Rodriguez	175	SE	Online: Miami, FL	PLHA	X		(-)	(+)	(-)	(-)
Rungkitwattanakul	90	National	Hemodialysis centres	AA/Black	х		(-)	(-)	(-)	(-)
Ryerson	56,749	National	Telephone	PWD	х		(-)	(+)	(+)	
Salmon	2525	National	Online	Racial/ethnic min.	х		(-)	(+/-)	(+)	(-)
Stephenson	290	National	Data obtained from the Love and Sex in the Time of COVID-19 study	LGBTQ+	x			(+)	(+)	
Stern	5110	National	Correctional and detention facilities	JI	X		(-)	(-)	(-)	(-)
Stoler	1040	National	Online	AA/Black	X		(-)	(+)		
Teixeira da Silva	1350	National	Online	LGBTQ+	X		(-)	(+/-)		(-)
Tsapepas	664	NE	Telephone: New York City, NY	Racial/ethnic min.		X	(-)			(-)
Uhr	701	National	Online	PWD	x		(+/-)	(+)	(-)	(-)
Wagner	1138	MW	Data obtained from the Detroit Metro Area Community Study	AA/Black	X		(-)			(-)
Wang	293	NE	Online: DE	AA/Black	X		(-)			(-)
Xiang	401	W	Online: Mainly OR, WA, and CA	PWD	X			(+/-)	(+)	(-)
Yang	387	National	Online	PWUD	X		(-)	(+/-)	(-)	(+)
Zhang	435	National	Online: Refugee communities	IMM	x		(-)	(+)		(-)

198 AA, African Americans; IMM, immigrants and refugees; JI, justice-involved people; Latinx, Latinx/Hispanic people; LGBTQ+,

199 Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people; PEH, people experiencing homelessness; PWD,

200 people with disabilities; PLHA, people living with HIV/AIDS; PWUD, people who use drugs; Racial/Ethnic min., racial/ethnic

201 minority.

202	Table 2 shows the number of focal articles by subpopulation, with 11 (22%) focused on
203	African American/Black people, 9 (18%) on people with disabilities, 4 (8%) on justice-involved
204	people, and 2 (4%) each on Latinx, people living with HIV/AIDS (PLHA), people who use drugs
205	(PWUD), and lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people. We allocated
206	findings from articles broadly focused on racial/ethnic minorities to each of the subpopulations
207	(i.e., African American/Black, Latinx, Asian, American Indian) for which disaggregated data
208	were provided (i.e., one article could be a "source" for several populations). Four additional
209	articles addressing VH pertaining to two subpopulations (e.g., African American/Black PLHA)
210	were each allocated as two sources. Table 2 shows the total number of sources (n=73) addressing
211	population-specific factors associated with VH across the 50 articles. Among these, 41.1% of
212	sources (n=30) identified VH factors among African American/Black populations, 17.8% (n=13)
213	Latinx populations, 12.3% (n=9) people with disabilities, and 5.5% (n=4) each Asian, justice-
214	involved, and PLHA.

Subpopulation	Focal articles on each sub- population	Additional sources addressing each subpopulation	Number (%) of total sources by sub- population (n=73)
African American/Black	11	19	30 (41)
Latinx	2	11	13 (18)
People with disabilities	9	0	9 (12)
Justice involved	4	0	4 (5)
People living with HIV/AIDS	2	2	4 (5)
Asian people	0	4	4 (5)
People who use drugs	2	1	3 (4)
Immigrants/refugees	1	1	2 (3)
LGBTQ+ people	2	0	2 (3)
People experiencing homelessness	1	0	1 (1)
American Indians/Native	0	1	1 (1)
Subtotal	34	39	73

#### 215 Table 2. Focal articles and additional sources by subpopulation

216 217

LGBTQ+, Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people

Fig 2 shows the number of articles addressing factors associated with VH in each of four domains: structural, social/community, individual, and Covid-19-vaccine-specific. Table 3 shows the domains of factors associated with VH in each subpopulation. Next, we describe findings based on a narrative synthesis of factors associated with VH and undervaccination for each focal population.

#### Fig 2. Count of articles identifying factors in each of the four domains of Covid-19 vaccine

- 225 hesitancy and underutilization
- 226

#### 227 Table 3. Population by domains of factors identified in Covid-19 vaccine hesitancy and

228 undervaccination

Subpopulation		Doma	lins	
	Structural	Social/Community	Individual	Vaccine-specific
African American/Black	Х	X	х	x
American Indian/Native American	Х			x
Asian	Х	X		x
Latinx	Х	X		x
LGBTQ+	Х	X	х	x
Immigrant/Refugee	Х	X		X
Justice-involved people	Х	X	х	x
People experiencing homelessness	Х	X	х	x
People living with HIV/AIDS	Х	X	Х	X
People with disabilities	Х	X	х	x
People who use drugs	Х		Х	X

LGBTQ+, Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people

#### 230 Black and African American people

231 Eleven articles focused exclusively on Covid-19 vaccination among Black/African 232 Americans [26,56,59,69,74,75,77,81,85,89,90], and 19 additional articles provided disaggregated 233 data—a total of 30 sources [46-48,49,51-53,55,60,65-68,70,73,82,84,86,92]. At the structural 234 level, 27 sources addressed the negative impacts of medical mistrust and distrust of government 235 on Covid-19 vaccination among Black and African Americans [26,46-49,51-53,55,59,65-70,73-236 75,77,81,82,84-86,89,92]. Several studies described Covid-19 VH, such as due to fears of being 237 experimented on with Covid-19 vaccines without consent, "based on...knowledge of historic 238 mistreatment and unethical research practices that adversely impacted black patients and 239 participants" [74, p.1786], including the legacy of the Tuskegee Study of untreated syphilis 240 [53,67,68,77]. Eleven sources addressed barriers to present-day healthcare and Covid-19 241 vaccines for Black/African Americans, including unemployment, housing insecurity, limited 242 interactions with HCP, and difficulties travelling to vaccination sites [48,52,53,56,68-243 70,75,77,89,90]. 244 At the social/community level, nine sources indicated the role of trust in HCPs in Covid-245 19 vaccination intentions [26,46,51,60,69,70,74,82,85]. Characteristic of many studies, "Blacks and Hispanics were more likely than Whites to state that it was 'extremely' important that a 246 247 medical professional of their same race/ethnicity endorse the vaccine before they took it" 248 [26,p.8]. Seven studies addressed the influence of families and communities on Covid-19 249 vaccination [48,52,59,70,74,77,81], and further that "governmental agencies are less well-250 received as information sources compared to friends or family" [59, p.1103]. In one study, 251 family influence promoted VH by casting doubt on public health information, rather than 252 motivating vaccination [81].

86342; this version posted February 23, 2023. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2023.02.23 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

253	At the individual level, four studies addressed negative impacts of religious beliefs,
254	including preference for 'natural' medicines over vaccines, and general vaccine aversion on
255	Covid-19 vaccination [67,74,77,81]. Covid-19 vaccine-specific concerns, identified in 14
256	studies, included vaccine safety, adverse effects, and uncertain efficacy [26,51-53,59,67-
257	70,73,74,77,81,90], and the importance of evidence of Covid-19 vaccine safety and efficacy
258	specific to Black/African Americans: "any data that's connected with some of the conditions that
259	are prevalent in our community" [53, p.8].
260	

260

#### *Latinx/Hispanic people* 261

262 Two studies focused on Covid-19 vaccination among Latinx/Hispanic people [50,61], 263 with an additional 11 sources providing data specific to this population

264 [26,46,48,49,53,60,67,68,70,73,82]. At the structural level, five studies identified negative

265 impacts of medical mistrust [48,49,61,67,82], including fear of being used as "guinea pigs

266 (conejillos de indias)" and of being sterilized [61]. Limited access to information in one's

267 preferred language, complicated online vaccination sign-up procedures, lack of insurance, and

268 lack of transportation to vaccination sites posed barriers to Covid-19 vaccination

269 [48,53,61,68,70]. Two studies underscored the importance of tailored vaccine education and

270 accessible information [68]: "[a family member] doesn't speak English...so, a lot of the

271 information that he may have heard about the vaccine and Covid probably came off of Univision

272 and Telemundo" [48, p.6].

273 At the social/community level, five studies described the important role of personal HCPs 274 in Covid-19 vaccination among Latinx communities [26,46,60,70,82], including endorsement 275 from an HCP of one's own ethnicity [26]. Two studies addressed altruism and wanting to protect

276	one's community as a motivator of Covid-19 vaccination [53,61]. Families and close
277	communities were described as playing an important role in Covid-19 vaccination knowledge
278	and decision-making [48,61,70]: "79% of the youth had discussed health with their families for
279	an average of 50 minutes [per week]" [61, p.753]. No individual-level factors were described,
280	but Covid-19 vaccine-specific concerns arose around safety, adverse effects, and efficacy
281	[26,61,67,68,70,73].

282

#### 283 Asian people

284 No studies focused exclusively on Covid-19 vaccination among people of Asian descent 285 in the U.S.; four sources provided disaggregated data on Asian people [46,53,64,67]. At the 286 structural level, barriers included difficulties in accessing reliable translations and messengers of 287 Covid-19 vaccine information [53]. Beyond linguistic translation, a Filipinx participant 288 explained, "In terms of translators...maybe those who may not be of the same culture or the way 289 that they're explaining the medical terminology may be intimidating" [53, p.6]. Medical mistrust 290 was identified as negatively impacting vaccination intention [53,67], with trust in personal HCPs 291 as sources of vaccine information positively associated with Covid-19 vaccination intention 292 among Asian people [46]. Covid-19 vaccine-specific concerns arose around safety, adverse 293 effects, and efficacy [53,64,67], including the need for population-specific evidence: "There has 294 been a lot of concerns in my family on how the vaccine works for people with heart disease, 295 which really affects...a lot of the Filipino community, and also those with respiratory diseases" 296 [53, p.6].

297

### 299 American Indians

300 No studies among those reviewed focused on Covid-19 vaccination among American 301 Indians or Alaskan Natives; one source provided data on American Indians [53]. Structural 302 factors arose regarding distrust of government, desire for autonomy ("to be respected)", 303 challenges in access to digital technology and the internet, lack of quality translations and 304 tailored information, lack of employment benefits, insurance, and transportation to get 305 vaccinated [53]. In addition to distrust ascribed to the politicization of vaccination, a participant 306 decried structural-level challenges for elders: "Some elders...they're houseless...there's no cell 307 phone, they ride public transportation. How is it going to get distributed [to them]...the most 308 vulnerable... it feels like our culture always gets the shitty end of the stick" [53, p.6]. Covid-19 309 vaccine-specific concerns arose around side effects, efficacy, and multiple doses—associated 310 with challenges for Native families due to the need for several trips to vaccination sites.

311

#### 312 *LGBTQ*+ *people*

313 Two sources focused on Covid-19 vaccination among LGBTO+ people [83,86]. At the 314 structural level, medical mistrust based on historical discrimination against sexual and gender 315 minorities was negatively associated with Covid-19 vaccination intentions [86]. Loss of 316 employment and housing insecurity were described as factors that underscored the threat of the 317 pandemic among LGBTO+ people, thus motivating vaccination. At the social and community 318 level, altruistic motivations were positively associated, while anticipated stigma was negatively 319 associated with vaccination intentions [83,86]. Individual-level factors impacting vaccination 320 were described in perceived threat of Covid-19: "negative experiences, along with the reported 321 high levels of perception of the seriousness of Covid-19 infection, are likely driving the high

levels of willingness to be vaccinated" [83,p.9]. Covid-19 vaccine-specific concerns included
adverse effects and safety [86].

324

#### 325 **People with disabilities**

326 Nine articles focused on challenges in Covid-19 vaccination for people with disabilities 327 (PWD) [12,57,58,64,67,72,76,88,91]. At the structural level, five studies addressed the impact of 328 trust in government: three reported a positive association with Covid-19 vaccination [57,58,88], 329 while two described governmental distrust contributing to VH [67,72]. Strict public health 330 measures and widespread reliance on digital technology during the pandemic posed structural 331 barriers in access to Covid-19 vaccination for PWD [12,72,76,88]. While PWD were described 332 as more likely than people without a disability to endorse Covid-19 vaccination, they were more 333 likely to report difficulties booking online vaccination appointments and locating and travelling 334 to vaccination sites [12].

335 At the social and community level, having a trusted HCP or clinic exerted a positive 336 influence on Covid-19 vaccination [12,57,76,88,91]. For example, among people living with 337 multiple sclerosis (MS), MS-specialist HCPs and the National MS Society were deemed trusted 338 sources: "well-positioned to provide accurate education about Covid-19 disease and vaccine 339 considerations...specific to the MS population as well as their individual patients" [57,p.3]. 340 At the individual level, perceived threat of Covid-19 was a positive correlate of Covid-19 341 vaccination among PWD, including individuals with chronic diseases and multiple comorbidities 342 [12,57,58,64,72,76,91]. Covid-19 vaccine-specific concerns included adverse effects, speed of

343 vaccine development, vaccine safety, and efficacy [58,64,67,72,76,88,91]. In addition to "safety

and efficacy...the top Covid-19 vaccination concerns", apprehension arose around "the effect of

the vaccine on MS symptoms and implications for [immunosuppressive] DMT [diseasemodifying therapy] use" [88, p.1078].

347

### 348 Justice-involved people

349 Four articles focused on Covid-19 vaccination among justice-involved (JI) individuals 350 (i.e., currently or formerly convicted or incarcerated) [54,63,66,84]. At the structural level, 351 medical mistrust and distrust of government exerted a negative impact on Covid-19 vaccination 352 among individuals in detention facilities [54,63,84] "based on their interactions with law 353 enforcement or the justice system or their experiences with institutional racism" [84, p.476]. A 354 study with incarcerated women described "a direct correlation between trust in the 355 pharmaceutical industry and willingness to receive the vaccine": "I've watched too many people 356 die because pharmaceuticals... So I don't know. Pharmaceutical companies just see a lot of big 357 money in there" [63, p.895]. One study described mitigation of structural-level barriers to Covid 358 -19 vaccination through tailored vaccine education and "early access to vaccine through a 359 dedicated federal allocation" for incarcerated individuals and facility staff [66,p.5889]. 360 At the social and community level, family and community influence was associated with 361 Covid-19 VH [54.63.66] among JI individuals in the absence of tailored public health 362 messaging: "The probable low health and informational literacy of these women leave them 363 vulnerable to influence from family and friends, many sharing and promoting disinformation and 364 conspiracy theories frequently shared by homegrown anti-vaccine organizations" [63, p.895]. 365 Social proofing exerted a positive influence: "some people may have been encouraged to accept 366 vaccination because they could see their peers being vaccinated" [54,66, p.5889]. 367 At the individual level, all four studies reported low perceived risk of contracting Covid-

19 as a correlate of VH among JI people [54,63,66,84]. A study in correctional and detention
facilities in 4 states reported that of participants (n=1823/5110) who would refuse Covid-19
vaccination, 18.9% (n=344/1823) "did not perceive themselves to be at risk for Covid-19 or
thought vaccination was unnecessary" [84, p.475]. Covid-19 vaccine-specific concerns arose
around vaccine safety and efficacy [54,63,84], which was associated with "lack of access to
reliable information" [54, p.375].

374

375 **People living with HIV/AIDS** 

376 Two articles focused on factors impacting Covid-19 vaccination intentions among PLHA 377 [70,80], with two additional sources providing PLHA-specific data [51,83]. At the structural 378 level, medical mistrust and distrust of government among PLHA were associated with lower 379 Covid-19 vaccination intentions [51,70,80]. A study with HIV-positive and predominantly 380 sexual minority Black Americans (n=101) indicated that "The most prevalent general mistrust 381 beliefs (endorsed by about half or more than half) concerned withholding information or a lack 382 of honesty by the government," which was correlated with VH [51, p.203]. A study with HIV-383 positive Black and Latinx Americans described unemployment being exacerbated by the 384 pandemic, with negative impacts on access to healthcare and Covid-19 vaccination [70]. At the 385 social and community level, the positive influence of personal HCPs as trusted sources of 386 information on Covid-19 vaccination was reported [51,70,80]: "Lower hesitancy scores were 387 present in participants who reported that they would get vaccinated if their provider 388 recommended it" [80, p.98].

At the individual level, perceived threat was associated with Covid-19 vaccination
 intentions: "...HIV-positive men may have more concerns about the seriousness and perceived

impact of Covid-19 infection on their health" [80, 83, p.9]. Covid-19 vaccine-specific concerns
arose around vaccine safety, adverse effects, and efficacy [51,70,80], with some PLHA
concerned that their health condition may make Covid-19 vaccination unsafe [80].

394

### 395 **People who use drugs**

396 Two studies focused on Covid-19 vaccination among people who use drugs (PWUD) 397 [73,92], with one additional source providing disaggregated data on PWUD [64]. At the 398 structural level, barriers to accessing healthcare and Covid-19 vaccines, as well as medical 399 mistrust and distrust in government were associated with lower Covid-19 vaccination intentions 400 [64,73]. One study noted vulnerability to misinformation among PWUD amid medical mistrust: 401 "As a marginalized population, patients with illicit drug use are often detached from and mistrust 402 the healthcare system—by extension, these patients may be more reliant on illegitimate 403 information sources" [64, p.803]. At the individual level, mask wearing was associated with 404 vaccine trust, both described as a function of accurate Covid-19 information [73]. Covid-19 405 vaccine-specific factors arose around safety and efficacy concerns that may negatively impact 406 uptake [73].

407

#### 408 Immigrants and refugees

One study focused on Covid-19 vaccination among immigrants and refugees [93], with
one additional source providing disaggregated data [61]. At the structural level, barriers to
healthcare and Covid-19 vaccine access were described as negatively impacting vaccination
[61,93]. A study with Latinx immigrant families identified "fear of encountering law
enforcement/immigration as barriers to access health care" [61, p.750]. Limited access to

414	information in one's preferred language, lack of reliable information from trusted sources,
415	constraints in access to the internet and digital technology, and lack of transportation and
416	employment benefits (i.e., paid sick days) were identified as barriers to Covid-19 vaccination
417	[93]. At the social and community level, family influence was demonstrated in a national online
418	survey of refugees (n=435): among those who reported intention to receive a Covid-19 vaccine,
419	nearly two-thirds (65.0%; n=199/306) indicated that it was motivated in part to protect their
420	family members [93]. Covid-19 vaccine-specific concerns about vaccine safety, adverse effects,
421	and efficacy were associated with VH, with two-thirds (71.3%; $n=92/129$ ) of refugees who
422	reported no intention or being unsure of accepting Covid-19 vaccination indicating concerns
423	about adverse effects [93].

- 424
- 425 **People experiencing homelessness**

426 One article focused on challenges to Covid-19 vaccination for people experiencing 427 homelessness [71]. At the structural level, Covid-19 VH was described as a function of "a more 428 general distrust of systems (e.g., health and homeless services) that are not designated to meet 429 their needs" [71, p.6]. Trusting the information received from friends, family, and social media 430 rather than "official news sources" was associated with greater Covid-19 VH [71]. At the 431 individual level, general vaccine aversion and low Covid -19 risk perception, and vaccine-432 specific concerns about safety, adverse effects, and efficacy were associated with VH among 433 people experiencing homelessness [71].

434

# 435 **Discussion**

436

This scoping review of Covid-19 vaccine hesitancy and broader underutilization of

437 Covid-19 vaccination provides evidence of multilevel determinants of delays or refusal of Covid-438 19 vaccination across marginalized populations in the U.S. Overall, a preponderance of 439 structural-level factors were identified that impact Covid-19 vaccination across marginalized 440 populations. Logistical and economic constraints including lack of transportation to distant 441 locales, lack of paid sick days, lack of availability of vaccination at familiar/local community 442 venues, and barriers in access due to being unemployed, unstably housed, 443 uninsured/underinsured, and the digital divide (i.e., access to digital technology and the internet, 444 and technical and financial ability to utilize it [94]) were compounded by lack of culturally and 445 linguistically appropriate information and access to trusted HCPs. Collectively, these findings 446 suggest that approaches to undervaccination among marginalized populations that focus 447 predominantly on individual-level, psychological factors may fail to capture the breadth and 448 impact of determinants of Covid-19 vaccination. 449 Importantly, we identified evidence for differential impacts of medical mistrust, as a

450 structural factor [29], and trust in a personal HCP or clinic, as a social/community factor. The 451 influence of medical mistrust reported with respect to government public health, healthcare 452 systems, and the pharmaceutical industry, emerged across multiple marginalized populations— 453 including African American, Latinx, LGBTQ+ populations, and their demographic 454 intersections—attributed in part to historical discrimination and past unethical medical research 455 and interventions, as well as present-day discrimination in healthcare and government 456 institutions. Nevertheless, having a trusted HCP, particularly with shared race or ethnicity 457 [26,51,69,70,74,82,85], or a familiar source of primary healthcare, mitigated Covid-19 VH— 458 despite broader mistrust of healthcare systems and government public health. JI populations, 459 PEH, and PWUD expressed medical mistrust due to generally negative experiences with

government and healthcare institutions. However, as in the case of JI populations, proactive
interventions to promote tailored education along with policy decisions to prioritize Covid-19
vaccination in prisons served to mitigate VH and promote vaccination [66].

463 Personal HCPs and usual care venues were widely reported to assuage concerns and 464 reduce VH, indicating a crucial role for primary healthcare [95]. In this light, the absence of 465 information from trusted sources tailored to address healthcare needs experienced as most 466 relevant to one's own community-reported among Black and Pilipino populations, PLHA and 467 PWD—and the lack of availability of Covid-19 and vaccine information in one's primary 468 language (reported among Latinx, Asian, and immigrant/refugee populations) emerged as 469 substantial missed opportunities to promote Covid-19 vaccination. Access to Covid-19 470 vaccination from a known HCP or clinic may be particularly important for marginalized 471 communities, who are more predisposed towards medical mistrust due to negative interactions 472 with the healthcare system and other societal institutions, and more vulnerable to discrimination 473 in healthcare [96,97].

474 Overall, the conflation of structural factors—documented in multifaceted barriers in 475 access to Covid-19 vaccination and systemic mistrust of healthcare systems-with individual 476 and social/community factors, such as perceived threat of Covid-19, perceived risk of 477 transmission, general vaccine attitudes, endorsement from one's personal HCP, and family 478 influence, each of which may impact on "decisional conflict" more specifically aligned with VH 479 [32], may fail to foster solutions that effectively address the identified problems [34,95,98]. 480 Moreover, the attribution of structural-level barriers to individual volition and deficits may 481 exacerbate alienation and mistrust among populations already marginalized due to systemic 482 discrimination, stigma, and adverse SDOH [96].

483 Interestingly, some of the same ostensible factors showed negative or positive 484 associations with VH depending on the population and context. For example, family influence 485 exerted a positive impact on Covid-19 vaccination among Latinx communities and 486 immigrant/refugee populations through familial sharing of health information and desire to 487 protect one's family. However, among other populations, the context of medical mistrust and the 488 virtual vacuum created by the absence of access to culturally tailored public health information 489 rendered family influence a liability, resulting in promulgation of conspiracy theories and 490 mistrust of Covid-19 vaccines among some African Americans [81], PEH [71], and JI persons 491 [63]. These examples underscore the importance of approaching VH as a population-specific and 492 context-dependent phenomenon [6,7]—in addition to disentangling the assessment of systemic 493 factors from individual-level and social/community concerns [99]. Consequently, the same 494 intervention applied to what might be understood as the same factor may exert opposite effects 495 on Covid-19 VH across different populations.

496 Finally, facilitators of Covid-19 vaccination emerged despite constraints. For example, 497 findings in common across PLHA and PWD-among whom one might reasonably expect 498 heightened concerns about vaccination due to underlying comorbidities and potential interactions 499 with routine medications—included the benefits of regular contact with a personal HCP or clinic; 500 this promoted trust in the vaccine information received and confidence in the HCP's ability to 501 address population-specific concerns. Furthermore, intersectional strengths reported regarding 502 Latinx immigrant and refugee populations included motivations to protect one's community and 503 cultural norms around familial sharing of health information, which served to mitigate VH. 504 Beyond a deficit model, community assets and sociocultural facilitators may be leveraged [100] 505 to support Covid-19 vaccination.

506 Findings from this scoping review should be understood in the context of limitations. 507 First, as a scoping review, our objective was to map and synthesize evidence on Covid-19 VH 508 and undervaccination among marginalized populations; we cannot draw causal conclusions about 509 the associations identified, nor was our aim to quantify Covid-19 vaccination intentions or 510 uptake, more apropos of meta-analysis. However, our scoping review methods reveal nuanced 511 information through synthesis of quantitative and qualitative findings on population-specific 512 barriers to Covid-19 vaccination and suggest important directions for future research. Second, 513 additional populations to those included might be characterized by marginalization, although we 514 based our focal populations on previous evidence and a priori criteria [42.43]. Third, while our 515 initial search comprised studies from the U.S. and Canada, no studies were identified from 516 Canada that met inclusion criteria during the specified time frame, possibly due to the later 517 availability of Covid-19 vaccination to the general adult population [41]. Studies published after 518 the time frame of our review might include additional populations, data, and study locales, 519 although we purposely focused on the initial introduction of Covid-19 vaccines before 520 subsequent booster doses and bivalent vaccines. Lastly, factors associated with VH and 521 underutilization of monovalent and bivalent boosters may differ from those revealed for initial 522 Covid-19 vaccination, although vaccine inequities remain [23].

In conclusion, we identified multilevel factors that influence Covid-19 VH and broader underutilization of Covid-19 vaccination, several of which may apply to other vaccinations. This scoping review suggests that distinguishing among individual and social/community factors that may fuel decisional ambivalence characteristic of Covid-19 VH—"a state of indecision and uncertainly about vaccination before a decision is made to act (or not act)" [35, p.58]—and factors attributable to systemic and structural barriers in access to vaccination and historically-

- justified mistrust of healthcare institutions, government public health, and the pharmaceutical industry, may support evidence informed strategies to promote Covid-19 vaccination among marginalized communities. Nevertheless, distilling and applying lessons from Covid-19 vaccination to effectively and equitably address VH and broader challenges in vaccine access may be contingent on resourcing and scaling up community partnerships and local health infrastructures [23,25,96,100], national population-specific public health initiatives to promote vaccination [101,102], and structural reforms beyond those traditionally associated with public
- 536 health.

### 537 Acknowledgements

- 538 We would like to thank Nalini Singh, University of Toronto Research Librarian, for assistance in
- 539 designing the literature search strategy and Dares Wotansirigul for uploading sources into
- 540 Covidence software.
- 541

### 542 Funding

543 This work was supported by the Canadian Institutes of Health Research [GA3-177731].

544

## 545 **Declaration of competing interest**

- 546 The authors declare the following financial interests/personal relationships which may be
- 547 considered as potential competing interests: Peter A. Newman is a member of the Editorial
- 548 Board of PLOS ONE.

## 550 **References**

- 551 1. Steele MK, Couture A, Reed C, Iuliano D, Whitaker M, Fast H, et al. Estimated number of
- 552 COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in
- the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385.
- 554 https://doi.org/10.1001/jamanetworkopen.2022.20385
- 555 2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the
- first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis.
- 557 2022;22(9):1293-302. <u>https://doi.org/10.1016/S1473-3099(22)00320-6</u>
- 3. Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, Yaron S. BNT162b2
- vaccine booster and mortality due to Covid-19. N Engl J Med. 2021;385(26):2413-20.
- 560 https://www.nejm.org/doi/10.1056/NEJMoa2115624
- 561 4. Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde AA, Douin DJ, et al. Early estimates of
- 562 bivalent mRNA vaccine effectiveness in preventing COVID-19–associated hospitalization
- among immunocompetent adults aged ≥65 Years IVY Network, 18 States, September
- 564 8–November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5152):1625-30.
- 565 <u>http://dx.doi.org/10.15585/mmwr.mm715152e2</u>
- 566 5. MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy:
- 567 definition, scope and determinants. Vaccine. 2015;33(34):4161-4.
- 568 <u>https://doi.org/10.1016/j.vaccine.2015.04.036</u>
- 569 6. SAGE Working Group. Report of the SAGE Working Group on vaccine hesitancy.
- 570 Geneva: WHO; 2014 Nov 12. Available from: <u>https://www.asset-</u>
- 571 scienceinsociety.eu/sites/default/files/sage\_working\_group\_revised\_report\_vaccine\_hesitan
- 572 <u>cy.pdf</u> [accessed 4 January 2023].

- 573 7. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring
- 574 trust in vaccination: a systematic review. Hum Vaccin Immunother. 2018;14(7):1599-609.
- 575 https://doi.org/10.1080/21645515.2018.1459252
- 576 8. Thomson A, Robinson K, Vallée-Tourangeau G. The 5As: a practical taxonomy for the
- 577 determinants of vaccine uptake. Vaccine. 2016;34(8):1018-24.
- 578 <u>https://doi.org/10.1016/j.vaccine.2015.11.065</u>
- 579 9. Gostin LO, Hodge JG Jr, Bloom BR, El-Mohandes A, Fielding J, Hotez P, et al. The public
- 580 health crisis of underimmunisation: a global plan of action. Lancet Infect Dis.
- 581 2020;20(1):e11-6. <u>https://doi:10.1016/S1473-3099(19)30558-4</u>
- 582 10. Baack BN, Abad N, Yankey D, Kahn KE, Razzaghi H, Brookmeyer K, et al. COVID-19
- 583 vaccination coverage and intent among adults aged 18-39 years United States, March-
- 584 May 2021. MMWR Morb Mortal Wkly Rep. 202170(25):928-33.
- 585 <u>http://dx.doi.org/10.15585/mmwr.mm7025e2</u>
- 586 11. Kriss JL, Hung MC, Srivastav A, Black CL, Lindley MC, Lee JT, et al. COVID-19
- 587 vaccination coverage, by race and ethnicity National Immunization Survey Adult COVID
- 588 Module, United States, December 2020-November 2021. MMWR Morb Mortal Wkly Rep.
- 589 2022;71(23):757-63. <u>http://dx.doi.org/10.15585/mmwr.mm7123a2</u>
- 590 12. Ryerson AB, Rice CE, Hung MC, Patel SA, Weeks JD, Kriss JL, et al. Disparities in
- 591 COVID-19 vaccination status, intent, and perceived access for noninstitutionalized adults,
- 592 by disability status National Immunization Survey Adult COVID Module, United States,
- 593 May 30-June 26, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(39):1365-71.
- 594 <u>https://doi.org/10.15585/mmwr.mm7039a2</u>

- 595 13. Shariff SZ, Richard L, Hwang SW, Kwong JC, Forchuk C, Dosani N, et al. COVID-19
- vaccine coverage and factors associated with vaccine uptake among 23,247 adults with a
- 597 recent history of homelessness in Ontario, Canada: a population-based cohort study. Lancet
- 598 Public Health. 2022;7(4):e366-77. https://doi.org/10.1016/s2468-2667(22)00037-8
- 599 14. Baah FO, Teitelman AM, Riegel B. Marginalization: conceptualizing patient vulnerabilities
- 600 in the framework of social determinants of health—an integrative review. Nurs Inq.
- 601 2019;26(1):e12268. <u>https://doi.org/10.1111/nin.12268</u>
- 602 15. Sharma M. Developing an integrated curriculum on the health of marginalized populations:
- successes, challenges, and next steps. J Health Care Poor Underserved. 2014;25(2):663-9.
- 604 <u>https://doi.org/10.1353/hpu.2014.0102</u>
- 16. Lau DT, Sosa P. Disparate impact of the COVID-19 pandemic and health equity data gaps.
- 606 Am J Public Health. 2022;112(10):1404-6. <u>https://doi.org/10.2105/AJPH.2022.307052</u>
- 607 17. World Health Organization. COVID-19 and the social determinants of health and health
- 608 equity: evidence brief. Geneva: WHO, Dec 6, 2021. Available from:
- 609 <u>https://www.who.int/publications/i/item/9789240038387</u> [accessed 5 January 2023].
- 610 18. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and ethnic
- 611 disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic
- 612 review. Ann Intern Med. 2021;174(3):362-73. <u>https://doi.org/10.7326/M20-6306</u>
- 613 19. Mude W, Oguoma VM, Nyanhanda T, Mwanri L, Njue C. Racial disparities in COVID-19
- 614 pandemic cases, hospitalisations, and deaths: a systematic review and meta-analysis. J Glob
- 615 Health. 2021;11:05015. <u>https://doi.org/10.7189/jogh.11.05015</u>
- 616 20. Hernandez I, Dickson S, Tang S, Gabriel N, Berenbrok LA, Guo J. Disparities in
- 617 distribution of COVID-19 vaccines across US counties: a geographic information system-

- based cross-sectional study. PLoS Med. 2022;19(7):e1004069.
- 619 https://doi.org/10.1371/journal.pmed.1004069
- 620 21. Siegel M, Critchfield-Jain I, Boykin M, Owens A, Muratore R, Nunn T, et al. Racial/ethnic
- 621 disparities in state-level COVID-19 vaccination rates and their association with structural
- 622 racism. J Racial Ethn Health Disparities. 2022;9(6):2361-74.
- 623 https://doi.org/10.1007/s40615-021-01173-7
- 624 22. Centers for Disease Control and Prevention. COVID data tracker. CDC, 2022. Available
- 625 from: <u>https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends</u> [accessed
- 626 5 January 2023].
- 627 23. Underhill K, Johnson OCA. Vaccination equity by design. Yale Law J. 2021;131:53-88.
- 628 24. Victora CG, Joseph G, Silva ICM, Maia FS, Vaughan JP, et al. The inverse equity
- 629 hypothesis: analyses of institutional deliveries in 286 national surveys. Am J Public Health.
- 630 2018;108(4):464-71. <u>https://doi.org/10.2105/AJPH.2017.304277</u>
- 631 25. Khubchandani J, Macias Y. COVID-19 vaccination hesitancy in Hispanics and African-
- 632 Americans: a review and recommendations for practice. Brain Behav Immun Health.
- 633 2021;15:100277. <u>https://doi.org/10.1016/j.bbih.2021.100277</u>
- 634 26. Kricorian K, Turner K. COVID-19 vaccine acceptance and beliefs among Black and
- 635 Hispanic Americans. PLoS One. 2021;16(8):e0256122.
- 636 https://doi.org/10.1371/journal.pone.0256122
- 637 27. Mohottige D, Boulware LE. Trust in American medicine: a call to action for health care
- 638 professionals. Hastings Cent Rep. 2020;50(1):27-9. <u>https://doi.org/10.1002/hast.1081</u>

- 639 28. Benkert R, Cuevas A, Thompson HS, Dove-Meadows E, Knuckles D. Ubiquitous yet
- 640 unclear: a systematic review of medical mistrust. Behav Med. 2019;45(2):86-101.
- 641 https://doi.org/10.1080/08964289.2019.1588220
- 642 29. Jaiswal J, Halkitis PN. Towards a more inclusive and dynamic understanding of medical
- 643 mistrust informed by science. Behav Med. 2019;45(2):79-85.
- 644 https://doi.org/10.1080/08964289.2019.1619511
- 645 30. Williams DR, Mohammed SA. Racism and health I: pathways and scientific evidence. Am
- 646 Behav Sci. 2013;57(8):1152-73. <u>https://doi.org/10.1177/0002764213487340</u>
- 647 31. Schuster M, Eskola J, Duclos P; SAGE Working Group on Vaccine Hesitancy. Review of
- vaccine hesitancy: Rationale, remit and methods. Vaccine. 2015;33(34):4157-60.
- 649 https://doi.org/10.1016/j.vaccine.2015.04.035
- 650 32. Larson HJ, Gakidou E, Murray CJL. The vaccine-hesitant moment. N Engl J Med.
- 651 2022;387(1):58-65. <u>https://doi.org/10.1056/nejmra2106441</u>
- 33. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an
- 653 overview. Hum Vaccin Immunother. 2013;9(8):1763-73. <u>https://doi.org/10.4161/hv.24657</u>
- 654 34. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
- refusal and access barriers: the need for clarity in terminology. Vaccine. 2018;36(44):6556-
- 656 8. <u>https://doi.org/10.1016/j.vaccine.2017.08.004</u>
- 657 35. Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, et al. Scoping
- reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol.
- 659 2014;67(12):1291-4. <u>https://doi.org/10.1016/j.jclinepi.2014.03.013</u>

- 660 36. Newman PA, Reid L, Tepjan S, Fantus S, Allan K, Nyoni T, et al. COVID-19 vaccine
- hesitancy among marginalized populations in the U.S. and Canada: protocol for a scoping
- 662 review. PLoS One. 2022;17(3):e0266120. <u>https://doi.org/10.1371/journal.pone.0266120</u>
- 663 37. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc
- 664 Res Methodol. 2005;8(1):19-32. <u>https://doi.org/10.1080/1364557032000119616</u>
- 665 38. Joanna Briggs Institute. Joanna Briggs institute reviewers' manual: 2015
- edition/supplement. Adelaide: The Joanna Briggs Institute; 2015.
- 667 39. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
- 668 Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern
- 669 Med. 2018;169(7):467-73. <u>https://doi.org/10.7326/m18-0850</u>
- 40. U.S. Department of Health & Human Services. Coronavirus: COVID-19 vaccines.
- 671 Washington: HHS, 2022 Dec 12. Available from: <u>https://www.hhs.gov/coronavirus/covid-</u>
- 672 <u>19-vaccines/index.html</u> [accessed 5 January 2023].
- 41. Health Canada. Health Canada authorizes first COVID-19 vaccine. Ottawa: Government of
- 674 Canada; 2020 Dec 9. Available from: <u>https://www.canada.ca/en/health-</u>
- 675 <u>canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html</u> [accessed 5
- 676 January 2023].
- 42. Palmer Kelly E, McGee J, Obeng-Gyasi S, Herbert C, Azap R, Abbas A, et al.
- 678 Marginalized patient identities and the patient-physician relationship in the cancer care
- 679 context: a systematic scoping review. Support Care Cancer. 2021;29(12):7195-207.
- 680 https://doi.org/10.1007/s00520-021-06382-8
- 43. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
- 682 Biometrics. 1977;33(1):159-74. <u>https://pubmed.ncbi.nlm.nih.gov/843571/</u>

- 683 44. Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of
- 684 rapid review methods. BMC Med. 2015;13:224. <u>https://doi.org/10.1186/s12916-015-0465-</u>
- 685 <u>6</u>
- 686 45. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al.
- 687 Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct
- rapid reviews. J Clin Epidemiol. 2021;130:13-22.
- 689 https://doi.org/10.1016/j.jclinepi.2020.10.007
- 690 46. Allen JD, Abuelezam NN, Rose R, Fontenot HB. Factors associated with the intention to
- 691 obtain a COVID-19 vaccine among a racially/ethnically diverse sample of women in the
- 692 USA. Transl Behav Med. 2021;11(3):785-92. <u>https://doi.org/10.1093/tbm/ibab014</u>
- 693 47. Arvanitis M, Opsasnick L, O'Conor R, Curtis LM, Vuyyuru C, Yoshino Benavente J, et al.
- Factors associated with COVID-19 vaccine trust and hesitancy among adults with chronic
- 695 conditions. Prev Med Rep. 2021;24:101484. <u>https://doi.org/10.1016/j.pmedr.2021.101484</u>
- 696 48. Balasuriya L, Santilli A, Morone J, Ainooson J, Roy B, Njoku A, et al. COVID-19 vaccine
- 697 acceptance and access among Black and Latinx communities. JAMA Netw Open.
- 698 2021;4(10):e2128575. <u>https://doi.org/10.1001/jamanetworkopen.2021.28575</u>
- 699 49. Battarbee AN, Stockwell MS, Varner M, Newes-Adeyi G, Daugherty M, Gyamfi-
- Bannerman C, et al. Attitudes toward COVID-19 illness and COVID-19 vaccination among
- 701 pregnant women: a cross-sectional multicenter study during August-December 2020. Am J
- 702 Perinatol. 2022;39(01):075-083. <u>https://doi.org/10.1055/s-0041-1735878</u>
- 50. Bauer C, Zhang K, Lee M, Jones M, Rodriguez A, de la Cerda I, et al. Real-time geospatial
- analysis identifies gaps in COVID-19 vaccination in a minority population. Sci Rep.
- 705 2021;11(1):18117. https://doi.org/10.1038/s41598-021-97416-y

- 51. Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, Mutchler MG, Dong L, et al. COVID-19
- related medical mistrust, health impacts, and potential vaccine hesitancy among Black
- Americans living with HIV. J Acquir Immune Defic Syndr. 2021;86(2):200-7.
- 709 https://doi.org/10.1097/qai.00000000002570
- 52. Bogart LM, Dong L, Gandhi P, Klein DJ, Smith TL, Ryan S, et al. COVID-19 vaccine
- 711 intentions and mistrust in a national sample of Black Americans. J Natl Med Assoc.
- 712 2022;113(6):599-611. <u>https://doi.org/10.1016/j.jnma.2021.05.011</u>
- 53. Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, et al.
- 714 COVID-19 vaccine decision-making factors in racial and ethnic minority communities in
- 715 Los Angeles, California. JAMA Netw Open. 2021;4(9):e2127582.
- 716 https://doi.org/10.1001/jamanetworkopen.2021.27582
- 717 54. Chin ET, Leidner D, Ryckman T, Liu YE, Prince L, Alarid-Escudero F, et al. Covid-19
- vaccine acceptance in California state prisons. N Engl J Med. 2021;385(4):374-6.
- 719 https://doi.org/10.1056/NEJMc2105282
- 720 55. Clark LR, Sawkin MT, Melton BL, Meyer EG. The COVID-19 vaccine conundrum: an
- assessment of vaccine hesitancy amongst patients at a federally qualified health center. J
- 722 Pharm Pract. 2022:8971900221116193. <u>https://doi.org/10.1177/08971900221116193</u>
- 56. Crozier J, Christensen N, Li P, Stanley G, Clark DS, Selleck C. Rural, underserved, and
- minority populations' perceptions of COVID-19 information, testing, and vaccination:
- report from a southern state. Popul Health Manag. 2022;25(3):413-22.
- 726 <u>https://doi.org/10.1089/pop.2021.0216</u>

- 57. Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19
- vaccination in adults with multiple sclerosis in the United States. Mult Scler Relat Disord.
- 729 2021;49:102788. <u>https://doi.org/10.1016/j.msard.2021.102788</u>
- 58. Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID-19 vaccine
- hesitancy in adults with multiple sclerosis in the United States: a follow up survey during
- the initial vaccine rollout in 2021. Mult Scler Relat Disord. 2021;54:103163.
- 733 https://doi.org/10.1016/j.msard.2021.103163
- 59. Fernández-Penny FE, Jolkovsky EL, Shofer FS, Hemmert KC, Valiuddin H, Uspal JE, et
- al. COVID-19 vaccine hesitancy among patients in two urban emergency departments.
- 736 Acad Emerg Med. 2021;28(10):1100-7. <u>https://doi.org/10.1111/acem.14376</u>
- 737 60. Fisher KA, Nguyen N, Crawford S, Fouayzi H, Singh S, Mazor KM. Preferences for
- 738 COVID-19 vaccination information and location: associations with vaccine hesitancy, race
- and ethnicity. Vaccine. 2021;39(45):6591-4. <u>https://doi.org/10.1016/j.vaccine.2021.09.058</u>
- 740 61. Garcia J, Vargas N, de la Torre C, Magana Alvarez M, Clark JL. Engaging Latino families
- about COVID-19 vaccines: a qualitative study conducted in Oregon, USA. Health Educ
- 742 Behav. 2021;48(6):747-57. https://doi.org/10.1177/10901981211045937
- 62. Garcia P, Montez-Rath ME, Moore H, Flotte J, Fults C, Block MS, et al. SARS-CoV-2
- vaccine acceptability in patients on hemodialysis: a nationwide survey. J Am Soc Nephrol.
- 745 2021;32(7):1575–81. <u>https://doi.org/10.1681/asn.2021010104</u>
- 63. Geana MV, Anderson S, Ramaswamy M. COVID-19 vaccine hesitancy among women
- 747 leaving jails: a qualitative study. Public Health Nurs. 2021;38(5):892-6.
- 748 <u>https://doi.org/10.1111/phn.12922</u>

- 64. Ghaffari-Rafi A, Teehera KB, Higashihara TJ, Morden FTC, Goo C, Pang M, et al.
- 750 Variables associated with coronavirus disease 2019 vaccine hesitancy amongst patients
- with neurological disorders. Infect Dis Rep. 2021;13(3):763-810.
- 752 https://doi.org/10.3390/idr13030072
- 753 65. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al.
- 754 Willingness to get the COVID-19 vaccine with and without emergency use authorization.
- 755 Am J Infect Control. 2021 Feb;49(2):137-42. <u>https://doi.org/10.1016/j.ajic.2020.11.018</u>
- 756 66. Hagan LM, Dusseau C, Crockett M, Rodriguez T, Long MJ. COVID-19 vaccination in the
- Federal Bureau of Prisons, December 2020-April 2021. Vaccine. 2021;39(40):5883-90.
- 758 <u>https://doi.org/10.1016/j.vaccine.2021.08.045</u>
- 759 67. Iadarola S, Siegel JF, Gao Q, McGrath K, Bonuck KA. COVID-19 vaccine perceptions in
- 760 New York State's intellectual and developmental disabilities community. Disabil Health J.

761 2022;15(1):101178. <u>https://doi.org/10.1016/j.dhjo.2021.101178</u>

- 762 68. Jimenez ME, Rivera-Núñez Z, Crabtree BF, Hill D, Pellerano MB, Devance D, et al. Black
- and Latinx community perspectives on COVID-19 mitigation behaviors, testing, and
- 764 vaccines. JAMA Netw Open. 2021;4(7):e2117074.
- 765 https://doi.org/10.1001/jamanetworkopen.2021.17074
- 766 69. Johnson KD, Akingbola O, Anderson J, Hart J, Chapple A, Woods C, Yeary K, McLean A.
- 767 Combatting a "Twin-demic": a quantitative assessment of COVID-19 and influenza
- vaccine hesitancy in primary care patients. Health Promot Perspect. 2021;11(2):179-85.
- 769 <u>https://doi.org/10.34172/hpp.2021.22</u>
- 770 70. Jones DL, Salazar AS, Rodriguez VJ, Balise RR, Starita CU, Morgan K, et al. Severe acute
- respiratory syndrome coronavirus 2: vaccine hesitancy among underrepresented racial and

- ethnic groups with HIV in Miami, Florida. Open Forum Infect Dis. 2021;8(6):ofab154.
- 773 <u>https://doi.org/10.1093/ofid/ofab154</u>
- 774 71. Kuhn R, Henwood B, Lawton A, Kleva M, Murali K, King C, et al. COVID-19 vaccine
- access and attitudes among people experiencing homelessness from pilot mobile phone
- survey in Los Angeles, CA. PLoS One. 2021;16(7):e0255246.
- 777 https://doi.org/10.1371/journal.pone.0255246
- 778 72. Luo H, Qu H, Basu R, Rafferty AP, Patil SP, Cummings DM. Willingness to get a COVID-
- 19 vaccine and reasons for hesitancy among Medicare beneficiaries: results from a national
- survey. J Public Health Manag Pract. 2022;28(1):70-6.
- 781 https://doi.org/10.1097/phh.00000000001394
- 782 73. Masson CL, McCuistian C, Straus E, Elahi S, Chen M, Gruber VA, et al. COVID-19
- vaccine trust among clients in a sample of California residential substance use treatment
- programs. Drug Alcohol Depend. 2021;225:108812.
- 785 https://doi.org/10.1016/j.drugalcdep.2021.108812
- 786 74. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J.
- 787 Understanding drivers of coronavirus disease 2019 vaccine hesitancy among Blacks. Clin
- 788 Infect Dis. 2021;73(10):1784-9. <u>https://doi.org/10.1093/cid/ciab102</u>
- 789 75. Moore JX, Gilbert KL, Lively KL, Laurent C, Chawla R, Li C, et al. Correlates of COVID-
- 19 vaccine hesitancy among a community sample of African Americans living in the
- southern United States. Vaccines. 2021;9(8):879. <u>https://doi.org/10.3390/vaccines9080879</u>
- 792 76. Myers A, Ipsen C, Lissau A. COVID-19 vaccination hesitancy among Americans with
- disabilities aged 18-65: an exploratory analysis. Disabil Health J. 2022;15(1):101223.
- 794 https://doi.org/10.1016/j.dhjo.2021.101223

- 795 77. Okoro O, Kennedy J, Simmons G Jr, Vosen EC, Allen K, Singer D, et al. Exploring the
- scope and dimensions of vaccine hesitancy and resistance to enhance COVID-19
- vaccination in Black communities. J Racial Ethn Health Disparities. 2022;9(6):2117-30.
- 798 https://doi.org/10.1007/s40615-021-01150-0
- 799 78. Razzaghi H, Meghani M, Pingali C, Crane B, Naleway A, Weintraub E, et al. COVID-19
- 800 vaccination coverage among pregnant women during pregnancy eight integrated health
- care organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal
- 802 Wkly Rep. 2021;70(24):895-9. <u>https://doi.org/10.15585/mmwr.mm7024e2</u>
- 803 79. Rodriguez RM, Torres JR, Chang AM, Haggins AN, Eucker SA, O'Laughlin KN, et al. The
- 804 rapid evaluation of COVID-19 vaccination in emergency departments for underserved
- 805 patients study. Ann Emerg Med. 2021;78(4):502-10.
- 806 <u>https://doi.org/10.1016/j.annemergmed.2021.05.026</u>
- 807 80. Rodriguez VJ, Alcaide ML, Salazar AS, Montgomerie EK, Maddalon MJ, Jones DL.
- 808 Psychometric properties of a vaccine hesitancy scale adapted for COVID-19 vaccination
- among people with HIV. AIDS Behav. 2022;26(1):96-101. <u>https://doi.org/10.1007/s10461-</u>
- 810 <u>021-03350-5</u>
- 811 81. Rungkitwattanakul D, Yabusaki A, Singh D, Lawson P, Nwaogwugwu U, Iheagwara OS,
- 812 et al. COVID-19 vaccine hesitancy among African American hemodialysis patients: a
- single-center experience. Hemodial Int. 2021;25(3):410-2.
- 814 <u>https://doi.org/10.1111/hdi.12922</u>
- 815 82. Salmon DA, Dudley MZ, Brewer J, Kan L, Gerber JE, Budigan H, et al. COVID-19
- 816 vaccination attitudes, values and intentions among United States adults prior to emergency

- 817 use authorization. Vaccine. 2021;39(19):2698-711.
- 818 https://doi.org/10.1016/j.vaccine.2021.03.034
- 819 83. Stephenson R, Sullivan SP, Pitter RA, Hunter AS, Chavanduka TM. COVID-19 pandemic
- 820 optimism and vaccine willingness among an online sample of US gay, bisexual, and other
- men who have sex with men. Vaccines. 2021;9(7):745.
- 822 <u>https://doi.org/10.3390/vaccines9070745</u>
- 823 84. Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, et al. Willingness to
- receive a COVID-19 vaccination among incarcerated or detained persons in correctional
- and detention facilities four states, September-December 2020. MMWR Morb Mortal
- 826 Wkly Rep. 2021;70(13):473-7. https://doi.org/10.15585/mmwr.mm7013a3
- 827 85. Stoler J, Enders AM, Klofstad CA, Uscinski JE. The limits of medical trust in mitigating
- 828 COVID-19 vaccine hesitancy among Black Americans. J Gen Intern Med.
- 829 2021;36(11):3629-31. <u>https://doi.org/10.1007/s11606-021-06743-3</u>
- 830 86. Teixeira da Silva D, Biello K, Lin WY, Valente PK, Mayer KH, Hightow-Weidman L, et
- al. COVID-19 vaccine acceptance among an online sample of sexual and gender minority
- men and transgender women. Vaccines. 2021;9(3):204.
- 833 <u>https://doi.org/10.3390/vaccines9030204</u>
- 834 87. Tsapepas D, Husain SA, King KL, Burgos Y, Cohen DJ, Mohan S. Perspectives on
- 835 COVID-19 vaccination among kidney and pancreas transplant recipients living in New
- 836 York City. Am J Health Syst Pharm. 2021;78(22):2040-5.
- 837 <u>https://doi.org/10.1093/ajhp/zxab272</u>
- 838 88. Uhr L, Mateen FJ. COVID-19 vaccine hesitancy in multiple sclerosis: a cross-sectional
- 839 survey. Mult Scler. 2022;28(7):1072-80. <u>https://doi.org/10.1177/13524585211030647</u>


- 840 89. Wagner AL, Sheinfeld Gorin S, Boulton ML, Glover BA, Morenoff JD. Effect of vaccine
- 841 effectiveness and safety on COVID-19 vaccine acceptance in Detroit, Michigan, July 2020.
- 842 Hum Vaccin Immunother. 2021;17(9):2940-5.
- 843 https://doi.org/10.1080/21645515.2021.1917233
- 844 90. Wang SX, Bell-Rogers N; FNP-c, Dillard D, Harrington MA. COVID-19 vaccine hesitancy
- in Delaware's underserved communities. Dela J Public Health. 2021;7(4):168-75. doi:
- 846 10.32481/djph.2021.09.022
- 847 91. Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI, Wooliscroft L. COVID-19
- 848 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl
- 849 Clin. 2021;7(2):20552173211017159. <u>https://doi.org/10.1177/20552173211017159</u>
- 850 92. Yang Y, Dobalian A, Ward KD. COVID-19 vaccine hesitancy and its determinants among
- adults with a history of tobacco or marijuana use. J Community Health. 2021;46(6):1090-8.
- 852 <u>https://doi.org/10.1007/s10900-021-00993-2</u>.
- 853 93. Zhang M, Gurung A, Anglewicz P, Subedi P, Payton C, Ali A, et al. Acceptance of
- 854 COVID-19 vaccine among refugees in the United States. Public Health Rep.
- 855 2021;136(6):774-81. <u>https://doi.org/10.1177/00333549211045838</u>
- 856 94. Ramsetty A, Adams C. Impact of the digital divide in the age of COVID-19. J Am Med
- 857 Informatics Assoc. 2020;22(7):1147-8. <u>https://doi.org/10.1093/jamia/ocaa078</u>
- 858 95. Ratzan S, Schneider EC, Hatch H, Cacchione J. Missing the point how primary care can
- overcome Covid-19 vaccine "hesitancy". N Engl J Med. 2021;384(25):e100.
- 860 <u>https://doi.org/10.1056/nejmp2106137</u>

- 861 96. Dada D, Djiometio JN, McFadden SM, Demeke J, Vlahov D, Wilton L, et al. Strategies
- that promote equity in COVID-19 vaccine uptake for Black communities: a review. J
- 863 Urban Health. 2022;99(1):15-27. https://doi.org/10.1007/s11524-021-00594-3
- 864 97. Rodriguez RM, Nichol G, Eucker SA, Chang AM, O'Laughlin KN, Pauley A, et al. Effect
- 865 of COVID-19 vaccine messaging platforms in emergency departments on vaccine
- acceptance and uptake: a cluster randomized clinical trial. JAMA Intern Med. 2022.
- 867 https://doi.org/10.1001/jamainternmed.2022.5909
- 868 98. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy: clarifying
- a theoretical framework for an ambiguous notion. PLoS Curr.
- 870 2015;7:ecurrents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289.
- 871 https://doi.org/10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289
- 872 99. Sturgis P, Brunton-Smith I, Jackson J. Trust in science, social consensus and vaccine
- 873 confidence. Nat Hum Behav. 2021;5(11):1528-34. <u>https://doi.org/10.1038/s41562-021-</u>
- 874 <u>01115-7</u>
- 875 100. Rubincam C, Lacombe-Duncan A, Newman PA. Taking culture seriously in biomedical
- 876 HIV prevention trials: a meta-synthesis of qualitative studies. Expert Rev Vaccines.
- 877 2015;15(3):331-47. https://doi.org/10.1586/14760584.2016.1118349
- 878 101. Demeke J, Ramos SR, McFadden SM, Dada D, Nguemo Djiometio J, Vlahov D, et al.
- 879 Strategies that promote equity in COVID-19 vaccine uptake for Latinx communities: a
- review. J Racial Ethn Health Disparities. 2022:1-9. https://doi.org/10.1007/s40615-022-
- 881 <u>01320-8</u>
- 882 102. U.S. Department of Health and Human Services. Campaign approach to reaching Black
- audiences. Washington: HHS, 2022 Sep 19. Available from:


- 884 <u>https://wecandothis.hhs.gov/resource/campaign-approach-to-reaching-black-audiences</u>
- [accessed 5 January 2023].
- 886 103. Centers for Disease Control and Prevention. Guidance for vaccinating older adults and
- people with disabilities: ensuring equitable COVID-19 vaccine access. Atlanta: CDC, 2022
- 888 Jan 20. Available from: <u>https://www.cdc.gov/vaccines/covid-19/clinical-</u>
- 889 <u>considerations/older-adults-and-disability/access.html [accessed 5 January 2023]</u>.
- 890

## 891 Supporting information

892 S1 Table. Sample search string



## Figure 1



## Figure 2